The purpose of the study is to establish the equivalence of GerEpo with the standard
treatment Eprex® for a treatment period of 12 weeks in patients on Hemodialysis with respect
to hemoglobin response and to establish the longer-term safety profile of GerEpo, with
special regards for the occurrence of Pure Red Cell Aplasia (PRCA) and other immunogenicity
related adverse event